Page 38 - Read Online

Page 18 of 18 Llamoza-Torres et al. Metab Target Organ Damage 2024;4:40 https://dx.doi.org/10.20517/mtod.2024.64

135. Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line
treatment for unresectable hepatocellular carcinoma (uHCC): first results from checkmate 9DW. JCO 2024;42:LBA4008. DOI
136. Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-6.
DOI PubMed PMC
+
137. Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4 T lymphocyte loss and promotes hepatocarcinogenesis. Nature
2016;531:253-7. DOI PubMed PMC
138. Heinrich B, Brown ZJ, Diggs LP, et al. Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice.
Gastroenterology 2021;160:331-45.e6. DOI PubMed PMC
+
139. Dudek M, Pfister D, Donakonda S, et al. Auto-aggressive CXCR6 CD8 T cells cause liver immune pathology in NASH. Nature
2021;592:444-9. DOI PubMed
140. Dudek M, Tacke F. Immature neutrophils bring anti-PD-1 therapy in NASH-HCC to maturity. Gut 2022;Online ahead of print. DOI
PubMed
141. Leslie J, Mackey JBG, Jamieson T, et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 2022;71:2093-106. DOI
PubMed PMC
142. Espinoza M, Muquith M, Lim M, Zhu H, Singal AG, Hsiehchen D. Disease etiology and outcomes after atezolizumab plus
bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150. Gastroenterology 2023;165:286-8.e4. DOI PubMed
143. Llovet JM, Heikenwalder M. Atezolizumab plus bevacizumab in advanced HCC: efficacy in NASH-specific etiology.
Gastroenterology 2023;165:1308-10. DOI PubMed
144. Dong T, Li J, Liu Y, et al. Roles of immune dysregulation in MASLD. Biomed Pharmacother 2024;170:116069. DOI PubMed
145. Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma.
Hepatology 2023;77:1773-96. DOI PubMed PMC
146. Zhou PY, Zhou C, Gan W, et al. Single-cell and spatial architecture of primary liver cancer. Commun Biol 2023;6:1181. DOI
PubMed PMC
147. Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses in the development of NAFLD-associated liver cancer
and prospects for therapeutic modulation. J Hepatol 2023;79:538-51. DOI PubMed
148. Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD/MASH-related HCC. Hepatology 2024;Online ahead of print. DOI
PubMed PMC
149. Guilliams M, Bonnardel J, Haest B, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage
niches. Cell 2022;185:379-96.e38. DOI PubMed PMC
+
+
150. Tan J, Fan W, Liu T, et al. TREM2 macrophages suppress CD8 T-cell infiltration after transarterial chemoembolisation in hepatocellular
carcinoma. J Hepatol 2023;79:126-40. DOI PubMed
151. Meyer T, Galani S, Lopes A, Vogel A. Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-
analysis confirms benefit in those with non-viral liver disease. J Hepatol 2023;79:e73-6. DOI PubMed
152. Rivera-Esteban J, Muñoz-Martínez S, Higuera M, et al. Phenotypes of metabolic dysfunction-associated steatotic liver disease-
associated hepatocellular carcinoma. Clin Gastroenterol Hepatol 2024;22:1774-89.e8. DOI PubMed
153. Tabrizian P, Holzner M, Ajmera V, et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving
immunotherapy before liver transplant: the multicenter VITALITY study. J Hepatol 2024;Online ahead of print. DOI PubMed